key: cord-0745918-6cyqq1bw
authors: Gao, Xiang; Dong, Qunfeng
title: A Bayesian Framework for Estimating the Risk Ratio of Hospitalization for People with Comorbidity Infected by SARS-CoV-2 Virus
date: 2020-09-28
journal: J Am Med Inform Assoc
DOI: 10.1093/jamia/ocaa246
sha: 3ec7a0924eff7549576d2f561abb5e90c765fc9e
doc_id: 745918
cord_uid: 6cyqq1bw

OBJECTIVE: Estimating the hospitalization risk for people with comorbidities infected by the SARS-CoV-2 virus is important for developing public health policies and guidance. Traditional biostatistical methods for risk estimations require: (i) the number of infected people who were not hospitalized, which may be severely undercounted since many infected people were not tested; (ii) comorbidity information for people not hospitalized, which may not always be readily available. We aim to overcome these limitations by developing a Bayesian approach to estimate the risk ratio of hospitalization for COVID-19 patients with comorbidities. MATERIALS AND METHODS: We derived a Bayesian approach to estimate the posterior distribution of the risk ratio using the observed frequency of comorbidities in COVID-19 patients in hospitals and the prevalence of comorbidities in the general population. We applied our approach to two large-scale datasets in the United States: 2491 patients in the COVID-NET, and 5700 patients in New York hospitals. RESULTS: Our results consistently indicated that cardiovascular diseases carried the highest hospitalization risk for COVID-19 patients, followed by diabetes, chronic respiratory disease, hypertension, and obesity, respectively. DISCUSSION: Our approach only needs (i) the number of hospitalized COVID-19 patients and their comorbidity information, which can be reliably obtained using hospital records, and (ii) the prevalence of the comorbidity of interest in the general population, which is regularly documented by public health agencies for common medical conditions. CONCLUSION: We developed a novel Bayesian approach to estimate the hospitalization risk for people with comorbidities infected with the SARS-CoV-2 virus.

To provide such an estimation, traditional biostatistical methods (e.g., logistic regression) require knowing both the number of infected people who were hospitalized and the number of infected people who were not hospitalized. Although the number of infected people who were hospitalized might be tallied from hospital records, the number of infected people who were not hospitalized may be difficult to estimate. The reason is that the official count of infected people who were not hospitalized is limited to those tested for the virus. Since not everyone infected by the virus is tested, the number of infected people not hospitalized may be undercounted in the traditional analysis. In addition, comorbidity information for people not hospitalized may not always be readily available for traditional biostatistical analyses. For example, Petrilli et al 4 recently applied multiple logistic regression to identify factors associated with hospital admission using a prospective cohort, but they had stated two main limitations in their study regarding the patients who were not hospitalized: (i) many confirmed patients might not have had their detailed medical history recorded for the study, and (ii) many potential patients might have been omitted from the study since they were not tested for the virus.

To overcome these limitations, we developed a Bayesian approach to estimate the risk ratio of hospitalization for COVID-19 patients with comorbidities. The risk ratio is defined as a ratio of the probability of hospitalization for the infected people with a particular comorbidity (e.g., diabetes) versus the probability of hospitalization for the infected people without any comorbidities. In other words, people without any comorbidities are used as reference for the risk ratio estimation. Our Bayesian approach only needs (i) the number of hospitalized COVID-19 patients and their comorbidity information, which can be reliably obtained using hospital records, and (ii) the prevalence of the comorbidity of interest in the general population, which is regularly documented by public health agencies for common medical conditions (e.g., hypertension, obesity, and diabetes). By applying our approach to two different largehttps://mc.manuscriptcentral.com/jamia scale datasets in the U.S., we obtained consistent results showing that cardiovascular disease had the highest elevated risk of hospitalization, followed by diabetes, chronic respiratory diseases, hypertension, and obesity, respectively.

The overview of our Bayesian model is depicted in the figure 1. We classify people in the general population into three categories: (1) h -the people without any known comorbidities, (2) c -the people with a particular comorbidity of interest (e.g., diabetes), who may or may not carry other types of comorbidities, and (3) (3) are shown as follows:

Dividing Eq. (5) by Eq. (4), we obtain the expression of  c / h as follows:

To estimate the posterior probability of  c / h, we need to sample from the following posterior distribution:

To specify the prior distribution for , we chose a Dirichlet distribution 8 as it is commonly used as the conjugate prior of the multinomial likelihood described in Eq. (1).

where a 1 , a 2 , a 3 correspond to the shape parameters of Dirichlet distribution. For this study, we set a 1 = a 2 = a 3 = 1 to set a uniform prior, although those values can be adjusted to more accurately reflect the probabilities of hospitalization for each category of patients if more data becomes available in the future. To specify the prior distributions for  h and  c , we chose beta distributions as they are commonly used to model proportions 8 .

https://mc.manuscriptcentral.com/jamia However,  h and  c are not unconstrained beta variables since  h +  c < 1 (i.e., the combined proportion of people without any medical conditions and people with a comorbidity of interest c is less than 100%). We implemented a constrained sampling strategy to enforce this constraint (see below). In addition,  h ,  h ,  c , and  c denote shape parameters of the corresponding beta distributions. Using the method of moments 8 , these parameters can be expressed as follows:

where  h and  h 2 , and  c and  c 2 represent the mean and variance of the proportions of the healthy people and people with the comorbidity of interest c, respectively, in the general population. Then, by plugging in the priors in Eq. (7), the posterior distribution becomes the following:

In summary, the foundation of our approach is based on our derived algebraic relationship (Eq. 6) between the quantity of  c / h (the risk ratio) and the quantities of  h,  c, and . Using a uniform Dirichlet distribution,  is modeled by a noninformative prior;  is related to the observed data (N, N h , N c , and N o ) in hospitalized COVID-19 patients through the multinomial likelihood as described in Eq. (1).  h and  c are modeled by informative priors using beta distributions whose shape parameters were expressed using the published prevalence rates for comorbidities in the general population.

https://mc.manuscriptcentral.com/jamia Through sampling from the posterior distribution of  h,  c, and , we were able to estimate the posterior distribution of  c / h as a derived quantity of  h  c / c  h with the constraint that the sum of  h and  c is less than one.

We used WinBUGS 9 (version 1.4.3) to implement the above models. In particular, the imposed constraint on the sum of  h and  c was implemented using the "ones trick" 10 conditions was estimated to be 12.2% (95% CI: 10.9-13.6) 17 .

We applied our Bayesian approach to a dataset 5 of hospitalized COVID-19 patients from the COVID-NET (n=2491). Table 1 

A different dataset 3 from the state of New York (n=5700) was used as a comparison.

The results from the New York dataset were similar to the ones from the COVID-NET dataset, showing that cardiovascular diseases (6.4, 4.9-8.5) and diabetes (4.8, 4.0-5.8) significantly increased the risk of hospitalization for COVID-19 patients, followed by 10 asthma (2.2, 1.8-2.6), hypertension (2.1, 1.8-2.5), COPD (1.7, 1.4-2.1), and obesity (1.4, 1.2-1.7) (Table 1, fig. 2B ). The only major difference in the ranking of the risk from the COVID-NET and the New York datasets was for COPD, with a lower risk estimated from the New York dataset compared to the COVID-NET dataset. greater than that of COVID-19 patients without any comorbidities. The hospitalization risk for COVID-19 patients also increased with chronic respiratory disease (asthma and COPD), hypertension, and obesity. These comorbidities were selected for this study since they were documented in both the COVID-NET and the New York datasets. Our preliminary exploration with the COVID-NET dataset also indicated elevated risks for people with autoimmune diseases, immune suppression conditions, and renal diseases (data not shown). We encourage other researchers to apply our Bayesian model to their own investigations.

One limitation with our current analysis is that our estimated hospitalization risk for patients with a comorbidity of interest (e.g., diabetes) may be confounded with other comorbidities in the same patient (e.g., hypertension). This limitation is attributed to our lack of access to the necessary data rather than our Bayesian approach per se. In this study, we relied upon two published summary statistics (i.e., COVID-NET and New York), which did not include the details of joint comorbidities in their publications 3, 5 . For researchers who can access the complete medical records (instead of just summary statistics), they would be able to obtain the frequency of joint comorbidities (e.g., number of COVID-19 hospitalized patients with both diabetes and hypertension). Then, our Bayesian approach could be applied directly to estimate the hospitalization risk for such joint comorbidities. Specifically, instead of using the frequency of a particular comorbidity (e.g., diabetes), our model would use the frequency of the joint comorbidities (e.g., diabetes and hypertension). In addition, the joint prevalence of comorbidities (e.g., diabetes and hypertension) would be used as informative priors.

The only biological assumption in our Bayesian model is that people in the general population, regardless of the status of their comorbidities, could be infected by the SARS-CoV-2 virus with similar probability (no assumptions on the severity of the symptoms after infection were made). This assumption is based on the rationale that SARS-CoV-2 is a newly emerged virus to the human population; thus, nobody is particularly immune to the virus. For example, it has been reported that viral loads were similar in asymptomatic and symptomatic patients 6 , and young children and adults were both similarly infected by the virus 7 . If future research shows that people with specified comorbidities do have a different chance of being infected, our Bayesian approach can be modified to accommodate that difference (e.g., using informative prior probability distributions to reflect the differential degrees of the chance of infection).

We developed a novel Bayesian approach to estimate the hospitalization risk for people with comorbidities infected with the SARS-CoV-2 virus. Our results indicated that cardiovascular diseases carried the highest hospitalization risk for COVID-19 patients, followed by diabetes, chronic respiratory disease, hypertension, and obesity, respectively. t c /t h = k h q c /k c q h subject to k h + k c < 1

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Bayesian Data Analysis

WinBUGS -a Bayesian modelling framework: concepts, structure, and extensibility

The BUGS Book: A Practical Introduction to Bayesian Analysis

Metabolic Syndrome and Related Disorders

We thank Drs. Lindsay Kim and Gayle E. Langley at the U.S. Centers for Disease Control and Prevention for providing the COVID-NET dataset for our analysis.

X.G. contributed project conception and data analysis, Q.D. contributed Bayesian modeling and drafting the manuscript.https://mc.manuscriptcentral.com/jamia

Funding None